We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Ifosfamide-based chemotherapy in locoregionally advanced nasopharyngeal cancer: evaluation of its role as neoadjuvant chemotherapy.
- Authors
Ghosh-Laskar S; Agarwal JP; Mohindra P; Sengar M; Vyas S; Pai VR; Budrukkar A; Pai P; D'Cruz AK; Dinshaw KA; Ghosh-Laskar, Sarbani; Agarwal, Jai Prakash; Mohindra, Pranshu; Sengar, Manju; Vyas, Shilpa; Pai, V R; Budrukkar, Ashwini; Pai, Prathamesh; D'Cruz, Anil K; Dinshaw, Ketayun Ardeshir
- Abstract
The use of Ifosfamide-based chemotherapy in primary nasopharyngeal carcinoma (NPC), in neoadjuvant settings [NACT] has not been sufficiently evaluated. We present here a retrospective analysis of 78 patients of untreated, locoregionally advanced NPC patients who received Ifosfamide-Cisplatin-based NACT at our institute from 1997 to 2004. Definitive treatment comprised radical radiotherapy (RT) or concurrent chemoradiotherapy (CCRT) using weekly Cisplatin. Post-NACT, 92% patients had a partial response (PR) while 3% had a complete locoregional response (CR). The rates of CR increased to 87% after completion of definitive treatment. With follow up (38 months), 29% patients developed recurrent/persistent disease. The local and locoregional control rates at 5 years were 76% and 73%, respectively. The 5-year overall survival (OAS) was 80% and disease-free survival was 65%. Grade III or more neutropenia was seen in 15%. Results of Ifosfamide-Cisplatin combination as a NACT in advanced NPC have been quite encouraging and need to be exploited further.
- Publication
Medical Oncology, 2009, Vol 26, Issue 4, p393
- ISSN
1357-0560
- Publication type
journal article
- DOI
10.1007/s12032-008-9135-2